IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq:ELGX) today announced that favorable data, which includes five-year patient follow-up data from the Company’s Powerlink® System pivotal clinical trial, supports the use of the Powerlink device in patients with anatomies considered difficult to treat with traditional endoluminal stent grafts (ELGs). The Powerlink System is being featured in three presentations at the International Congress XX on Endovascular Interventions being held February 11-15, 2007 in Scottsdale, Ariz
